Skip to content

Pager-Assisted Smoking Cessation Treatment

Pager-Assisted Smoking Cessation Treatment

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01207310
Acronym
Pager
Enrollment
224
Registered
2010-09-22
Start date
2003-05-31
Completion date
2005-12-31
Last updated
2017-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Smoking Cessation

Keywords

smoking, smoking of 10 cigarettes per day

Brief summary

The proposed study tests the efficacy of using pager-assisted messages combined with nicotine patches in facilitating smoking cessation and relapse prevention in a 2-arm randomized clinical trial. The hypothesis is that the proportion of biochemically-verified quitters at 3 and 12 months in the study arm randomized to receive therapeutic messages on alphanumeric pagers for 3 months along with individual smoking cessation counseling and nicotine patches will be greater that the proportion of biochemically-verified quitters who receive only individual smoking cessation counseling and nicotine patches.

Detailed description

A total of 224 current smokers were enrolled in a randomized controlled smoking cessation trial. Participants were community-living adult smokers of ≥10 cigarettes per day during the pre-enrollment week who were interested in quitting and recruited from the local area by means of print, media, and online advertisements. To be eligible, they needed to be smoking 10 or more cigarettes per day, aged 18 or older, motivated to quit smoking, prepared to set a quit date, willing to use nicotine patches, and able to come to therapy sessions and be followed by telephone. Participants in the pager treatment were provided with alpha-numeric pagers free of charge for three months. Using specially-designed communication software, text messages were sent to participants aimed at facilitating motivation to quit, cessation strategies, and coping skills to maintain abstinence. Participants in both treatment groups were seen for two 60-minute sessions of standard smoking cessation counseling, and received three follow-up phone calls and two months of nicotine patches.

Interventions

BEHAVIORALsmoking cessation counseling

two 60-minute face-to-face treatment sessions and three 20-minute follow-up contacts at weeks 2, 3, and 9

DRUGNicotine patch

8 weeks' worth of nicotine patches

DEVICEalphanumeric pager

therapeutic messages to be delivered for three months

Sponsors

University of California, San Francisco
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* smoking 10 or more cigarettes per day * aged 18 or older * motivated to quit smoking and prepared to set a quit date * willing to use nicotine patches * ability to come to therapy sessions and be followed by telephone

Exclusion criteria

* individuals who are psychotic * severely depressed * organically brain impaired * actively abusing alcohol or other substances, and/or who have been drug dependent during the past six months * terminally ill * unable to be contacted by phone,currently using nicotine replacement or smoking cessation medications * those with contraindications to nicotine patches, female smokers who are pregnant or breastfeeding

Design outcomes

Primary

MeasureTime frameDescription
biologically-validated point prevalence smoking cessation12 months after enrollmentAbstinence from cigarettes even a puff, other tobacco products and nicotine replacement for seven days at the 12 month follow-up date as validated by salivary cotinine less than 15 ng/ml

Secondary

MeasureTime frameDescription
continuous abstinence from cigarettes even a puff, tobacco products and nicotine replacement12 months after enrollmentmaintained cessation from smoking, biologically-validated by repeated measures of salivary cotinine less than 15 ng/ml at 12 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026